- Molecular NameIndapamide
- SynonymIndapamida [INN-Spanish]; Indapamidum [INN-Latin]
- Weight365.841
- Drugbank_IDDB00808
- ACS_NO26807-65-8
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)2.23
- pka8.8
- LogD (pH=7, predicted)2.22
- Solubility (experiment)0.0593 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-3.65
- LogSw (predicted, AB/LogsW2.0)0.05
- Sw (mg/ml) (predicted, ACD/Labs)0.08
- No.of HBond Donors4
- No.of HBond Acceptors6
- No.of Rotatable Bonds3
- TPSA109.67
- StatusFDA approved
- AdministrationN/A
- PharmacologyA non-thiazide sulphonamide diuretic drug marketed by Servier, generally used in the treatment of hypertension, as well as decompensated cardiac failure.
- Absorption_valueN/A
- Absorption (description)Rapidly absorbed after oral administration.
- Caco_2N/A
- Bioavailability90.0
- Protein binding80.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt is extensively metabolised
- Half life15 h
- Excretion60% of a dose is slowly excreted in the urine over a period of 8 days with less than 5% as unchanged drug. About 20% of a dose is slowly eliminated in the faeces.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySide effects include electrolyte imbalance (potassium or salt depletion due to too much fluid loss), nausea, stomach disorders, vomiting, weakness
- LD50 (rat)N/A
- LD50 (mouse)N/A